Full-Time

Sr. Medical Science Liaison

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$205k - $235kAnnually

+ Performance Bonus + Equity

Senior

Remote in USA

Focus on Ohio Valley region.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Candidates with a PharmD, Ph.D., MD, Genetic Counseling, as well as other advanced healthcare degrees or relevant experience, will be considered
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance is preferred, or at least 2 years of other relevant clinical or healthcare experience will be considered
  • Prior experience in rare diseases, cardiology, or neurology is preferred
  • Excellent interpersonal communication and presentation skills (including networking)
  • Able to participate in a scientific dialogue with KOLs and researchers
  • Excellent teaching skills and ability to present and discuss scientific material clearly and concisely
  • Proven ability to create and sustain relationships with industry leaders
  • Skilled in clinical research and an understanding of the process of pharmaceutical product development and approval
  • Demonstrated ability to organize, prioritize, and work effectively with minimal supervision in a constantly changing environment
  • Travel 50-60% of the time depending on territory size; evening and weekend work will be involved with some variation based upon the demands of the business imperatives
Responsibilities
  • Developing relationships with various healthcare professionals, and providing them with credible, fair, balanced, scientific information
  • Be a major source of balanced medical information for HCPs and will be skilled in issues management and addressing unsolicited questions about safety and off-label use of products based on available scientific data
  • Territory planning, identifying new external stakeholders, and understanding therapeutic area educational and data gaps in the community will be key activities. This plan may be dynamic with respect to the molecule, molecule life-cycle, therapeutic area, and territory. The MSL will liaise with key internal stakeholders to build a comprehensive action-oriented plan
  • Expected to become a therapeutic area and product expert. This will be evidenced by regular review of relevant literature and participation in scientific congresses and conferences, including training sessions, to establish and maintain an up-to-date knowledge base
  • Be instrumental in internal training and communication. Knowledge sharing, including KOL and site profiling, and education both internally and externally will be a key area of responsibility
  • Assist in the identification of potential investigators and research projects. This may include assistance with investigator-sponsored trial process, sponsored study site identification, recruitment strategies, and collaboration with clinical operations
Desired Qualifications
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance is preferred, or at least 2 years of other relevant clinical or healthcare experience will be considered
  • Prior experience in rare diseases, cardiology, or neurology is preferred

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient health. With over 15 drug programs targeting 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off